Portal de Periódicos da CAPES

Evaluation of aztreonam and ampicillin vs. amikacin and ampicillin for treatment of neonatal bacterial infections

1990; Lippincott Williams & Wilkins; Volume: 9; Issue: 3 Linguagem: Inglês

10.1097/00006454-199003000-00006

1532-0987

María A. Umaña, Carla Odio, Enrique Castro, José L. Salas, George H. McCracken,

Cystic Fibrosis Research Advances

In a prospective randomized, open study we evaluated aztreonam (AZ) for treatment of neonatal bacterial infections. There were 147 patients enrolled in the study; 75 received AZ and ampicillin (AMP) and 72 amikacin (AM) and AMP (conventional therapy). Twenty-eight AZ/AMP-treated patients and 32 conventionally treated patients had bacteriologically documented infections caused by gram-negative enteric bacilli or Pseudomonas species. Treatment groups were comparable in age, clinical status, and type and severity of underlying disease at the time of enrollment. Bronchopneumonia and infections caused by Pseudomonas species oc-